ABT · 8-K · 20261021PR066601

Exact Sciences Acquisition

ABBOTT LABORATORIES · 2026-10-21 · Importance 59 · Surprise 60 · In source text

Abbott completed its acquisition of Exact Sciences on March 23, 2026. The acquisition added $706 million of historical Exact Sciences sales to Abbott's comparable nine-month 2026 revenue reconciliation, including $681 million from the U.S. and $25 million internationally. Cancer Diagnostics reported $1.983 billion of nine-month sales, with comparable sales growth of 13.5% in the U.S. and 15.0% internationally. Nine-month 2026 acquisition-related specified items included $604 million of pretax costs, including accelerated equity-award expense, integration costs, and inventory step-up amortization.

Key facts

• Abbott completed acquisition of Exact Sciences on March 23, 2026 source
• Comparable sales growth includes the prior and current year sales of Exact Sciences following the March 23, 2026 acquisition source
• In 2025, total worldwide sales for Exact Sciences were $3.247 billion, including U.S. sales of $3.145 billion and international sales of $102 million source
• Third-quarter Non-GAAP revenue reconciliation shows adjustment includes historical sales for Exact Sciences prior to acquisition and the adjustment amount for Total Company was $40 million of foreign exchange to reach comparable revenue of $13,053 million source

Impact estimates